Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma

PR Newswire05-08

First dosing dohort was completed with complete response and disease stabilization identified at three months at the lowest dose level in the Phase 1 study No ACE1831-related serious adverse events, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2433874292?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Y.qMulLzkNn28gFBy.3ICw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c3f81a0afc9e1374519be281870519c1","is_english":true,"pubTime":"2024-05-08 19:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2433874292","market":"us","top_or_hot":-1,"title":"Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma","media":"PR Newswire","content":"<div>\n<p>First dosing dohort was completed with complete response and disease stabilization identified at three months at the lowest dose level in the Phase 1 study\nNo ACE1831-related serious adverse events, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/acepodia-announces-preliminary-clinical-data-110000137.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcepodia Announces Preliminary Clinical Data From Phase 1 Clinical Trial of ACE1831, First-Ever Anti-CD20 Antibody Conjugated Allogenic Gamma Delta T Cell Therapy for Non-Hodgkins Lymphoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-08 19:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/acepodia-announces-preliminary-clinical-data-110000137.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>First dosing dohort was completed with complete response and disease stabilization identified at three months at the lowest dose level in the Phase 1 study\nNo ACE1831-related serious adverse events, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/acepodia-announces-preliminary-clinical-data-110000137.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKVL7J92.USD","symbol_name":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","start_time":0,"source_url":"https://finance.yahoo.com/news/acepodia-announces-preliminary-clinical-data-110000137.html","article_id":"2433874292","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Y.qMulLzkNn28gFBy.3ICw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/c3f81a0afc9e1374519be281870519c1"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/acepodia-announces-preliminary-clinical-data-110000137.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2433874292","pubTimestamp":1715166000,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"First dosingdohort was completed with complete response and disease stabilization identified at three months at the lowest dose level in the Phase 1 study. No ACE1831-related serious adverse events, includingGvHD, neurotoxicity, high-grade CRS or dose limiting toxicities were observed. ALAMEDA, Calif. and TAIPEI, May 8, 2024 /PRNewswire/ -- Acepodia , a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation  and allogeneic gamma delta 2 (γδ2)T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma .\"This ongoing trial is the first to demonstrate potential clinical benefit to patients using biorthogonal chemistry and opens the door to a powerful, new approach for cell therapy that overcomes limitations of current C","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2552382058.USD":"WELLINGTON US BRAND POWER \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","SD":"SandRidge Energy","BK4086":"建筑产品","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","BK4588":"碎股","TT":"Trane技术","BK4213":"石油与天然气的勘探与生产","CR":"crane","LU0323240290.USD":"HSBC GIF GLOBAL EQUITY CLIMATE CHANGE \"AD\" INC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4504":"桥水持仓","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4161":"工业机械","LU2211817866.USD":"Allianz Food Security AT Acc USD"},"translate_title":"Acepodia公布ACE1831 1期临床试验的初步临床数据，ACE1831是首个抗CD20抗体缀合的同种异体γ δ T细胞治疗非霍奇金淋巴瘤的药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SD":1,"CR":1,"TT":0.9},"content_text":"First dosing dohort was completed with complete response and disease stabilization identified at three months at the lowest dose level in the Phase 1 study\nNo ACE1831-related serious adverse events, including GvHD, neurotoxicity, high-grade CRS or dose limiting toxicities were observed\nResults shared during a fireside chat hosted by William Blair & Company on May 7th, 2024. An archived recording will be available for 7 days following the event at https://www.acepodia.com/newsroom/media/. \n\nALAMEDA, Calif. and TAIPEI, May 8, 2024 /PRNewswire/ -- Acepodia (6976:TT), a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 (γδ2) T cell platforms to address gaps in cancer care, today announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin's lymphoma (NHL).\nKey Results From Preliminary Clinical Data\n\nOne out of five patients demonstrated complete response (CR) and three out of five patients experienced disease stabilization (SD) with single dose of ACE1831 at the lowest dose level. Among those patients, one CR and two SD patients were previously treated with CD19 CAR-T.\nDurability of clinical response was observed for three months after a single dose of ACE1831.\nThe lowest dose of ACE1831 was well tolerated with no ACE1831-related serious adverse events or dose limiting toxicities. Dose escalation is ongoing.\n\nACE1831 is Acepodia's first cell therapy to enter clinical development from its proprietary ACC platform, which uses biorthogonal chemistry to conjugate gamma delta 2 (γδ2) T cells with antibodies targeting CD20. The platform, based on the pioneering work of 2022 Nobel Prize laureate Dr. Carolyn Bertozzi that applied click chemistry to living systems, creates an off-the-shelf, non genetically engineered version of CAR-T cell therapy that is more easily scaled and avoids cytokine release storms, neurotoxity and other side effects associated with CAR-T cell therapies. The preliminary data demonstrates that ACE1831 activates both an innate and adaptive immune response by direct killing of tumor cells, tumor opsonization, and recruitment of T cells through cytokine secretion, and may therefore generate a more comprehensive immune response than standard CAR-T cell therapies. \n\"This ongoing trial is the first to demonstrate potential clinical benefit to patients using biorthogonal chemistry and opens the door to a powerful, new approach for cell therapy that overcomes limitations of current CAR-T cell therapies and is more accessible to patients,\" said Sonny Hsiao, Ph.D., chief executive officer of Acepodia. \"We are encouraged to see a robust and durable effect after a single treatment at the lowest dose, and remain focused on the continued development of this first-of-its kind treatment option.\"\nThe first-in-human, phase 1 trial is an open-label, dose escalation study that aims to evaluate the safety and tolerability, pharmacokinetics, and efficacy of ACE1831 in patients with relapsed/refractory non-Hodgkin's lymphoma. The multi-center trial is expected to enroll up to 42 patients in the United States and Taiwan.\nAbout ACE1831\nACE1831 is an off-the-shelf gamma delta T cell therapy candidate developed from Acepodia's proprietary ACC platform. ACE1831 targets CD20-expressing hematological cancers using anti-CD20 antibody conjugated gamma delta T cells. Taking advantage of the high expression of NK cell activating receptors of the gamma delta T cells to scavenge the malignant blood cells, ACE1831 has demonstrated in models enhanced cytotoxicity against cancer cells both in vitro and in vivo. ACE1831 is currently being evaluated in a Phase 1, first-in-human clinical trial for patients with non-Hodgkin's lymphoma.\nAbout Acepodia\nAcepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens.\nAcepodia is made up of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. For more information, visit www.acepodia.com and follow Acepodia on Twitter and LinkedIn.\n View original content:https://www.prnewswire.com/news-releases/acepodia-announces-preliminary-clinical-data-from-phase-1-clinical-trial-of-ace1831-first-ever-anti-cd20-antibody-conjugated-allogenic-gamma-delta-t-cell-therapy-for-non-hodgkins-lymphoma-302139302.html\nSOURCE Acepodia Inc.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433874292"}